Atea Pharmaceuticals, Inc.
AVIR
$3.65
$0.1153.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 47.69M | 51.35M | 53.89M | 49.32M | 47.46M |
| Gross Profit | -47.69M | -51.35M | -53.89M | -49.32M | -47.46M |
| SG&A Expenses | 42.93M | 46.08M | 48.85M | 47.02M | 48.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 146.70M | 140.70M | 171.47M | 165.07M | 164.77M |
| Operating Income | -146.70M | -140.70M | -171.47M | -165.07M | -164.77M |
| Income Before Tax | -135.27M | -138.59M | -167.46M | -172.96M | -174.95M |
| Income Tax Expenses | 861.00K | 897.00K | 925.00K | 1.05M | 1.04M |
| Earnings from Continuing Operations | -136.13 | -139.49 | -168.39 | -174.01 | -176.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -136.13M | -139.49M | -168.39M | -174.01M | -176.00M |
| EBIT | -146.70M | -140.70M | -171.47M | -165.07M | -164.77M |
| EBITDA | -146.28M | -140.29M | -171.05M | -164.66M | -164.35M |
| EPS Basic | -1.61 | -1.65 | -2.00 | -2.07 | -2.10 |
| Normalized Basic EPS | -0.93 | -0.87 | -1.08 | -1.02 | -1.01 |
| EPS Diluted | -1.61 | -1.65 | -2.00 | -2.07 | -2.10 |
| Normalized Diluted EPS | -0.93 | -0.87 | -1.08 | -1.02 | -1.01 |
| Average Basic Shares Outstanding | 337.79M | 338.30M | 337.06M | 336.03M | 335.01M |
| Average Diluted Shares Outstanding | 337.79M | 338.30M | 337.06M | 336.03M | 335.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |